# University of California, Irvine: Phase 1 study closed enrollment, 6 enrolled (Advanced Lung Non-Small Cell Carcinoma, Metastatic Lung Non-Small Cell Carcinoma)

**Score:** 30/100

| Field | Value |
|---|---|
| Sponsor | University of California, Irvine |
| Sponsor type | Academic and hospital |
| Study | Genetically Engineered Natural Killer (NK) Cells With or Without Atezolizumab for the Treatment of Non-small Cell Lung Cancer Previously Treated With PD-1 and/or PD-L1 Immune Checkpoint Inhibitors |
| NCT ID | NCT05334329 |
| Phase | Phase 1 |
| Status | active not recruiting |
| Conditions | Advanced Lung Non-Small Cell Carcinoma; Metastatic Lung Non-Small Cell Carcinoma; Recurrent Lung Non-Small Cell Carcinoma; Refractory Lung Non-Small Cell Carcinoma; Stage III Lung Cancer AJCC v8; Stage IIIA Lung Cancer AJCC v8 |
| Intervention types | biological, procedure, drug |
| Target enrollment | 6 |
| Site countries | United States |
| Posted | 2022-04-19 |
| Planned start | 2022-07-20 |
| Event | Enrollment closed (active, not recruiting) |
| Event date | 2026-10-06 |
| Last update posted | 2026-10-06 |

## Why this score
- Enrollment closed: data management, monitoring and closeout ahead.

Source: ClinicalTrials.gov (U.S. National Library of Medicine) API v2 (https://clinicaltrials.gov/study/NCT05334329). Last refreshed: 2026-11-05T08:46:16.625Z.
From public ClinicalTrials.gov registrations. Sponsor and study level only: we never list investigators, contacts or participants. A registration describes a planned study and can change. Status changes are read from each study's current status, actual dates and latest posted update, not a full change history, so an update can be a correction rather than a new change. Verify on ClinicalTrials.gov.